Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 Open-Label Extension in Fragile X Syndrome
NCT03802799Phase 3Active, not recruiting
- Sponsor
- Zynerba Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Jun 2026
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of Zygel in Fragile X syndrome (FXS), sponsored by Zynerba Pharmaceuticals. Started Nov 2018; status: active, not recruiting.
02
Drugs
Zygel
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT03802799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802799.